733
edits
Infective Endocarditis: Difference between revisions
→Therapy
| Line 129: | Line 129: | ||
In cases of prosthetic valve endocarditis (PVE), microbiological activity depends on early (<2 months post op) or late (>2 months post op). In early PVE S.aureus accounts for 40% of the cases, followed by coagulase negative staphylococcus (17%). In late PVE coagulase negative staphylococcus accounts for 20% of cases, followed by S. aureus (18%). Coverage for enterococci, streptococci, and gram negative should be considered in empiric therapy in both groups. Rifampin + Vancomycin + Gentamicin should be initiated for PVE <12 post op. Suspected PVE >12 months post op may be treated with the same regimen as for native valves.<cite>xvi</cite> | In cases of prosthetic valve endocarditis (PVE), microbiological activity depends on early (<2 months post op) or late (>2 months post op). In early PVE S.aureus accounts for 40% of the cases, followed by coagulase negative staphylococcus (17%). In late PVE coagulase negative staphylococcus accounts for 20% of cases, followed by S. aureus (18%). Coverage for enterococci, streptococci, and gram negative should be considered in empiric therapy in both groups. Rifampin + Vancomycin + Gentamicin should be initiated for PVE <12 post op. Suspected PVE >12 months post op may be treated with the same regimen as for native valves.<cite>xvi</cite> | ||
[http://circ.ahajournals.org/content/111/23/3167.full | The American Heart Association recommendation for specific antimicrobial therapy can be found in their [http://circ.ahajournals.org/content/111/23/3167.full guideline]. | ||
[http://eurheartj.oxfordjournals.org/content/30/19/2369.long | The European Society of Cardiology [http://eurheartj.oxfordjournals.org/content/30/19/2369.long guideline for the treatment of Infective endocarditis.] | ||
===Prophylaxis=== | ===Prophylaxis=== | ||